Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL
Status:
Completed
Trial end date:
2020-01-27
Target enrollment:
Participant gender:
Summary
Despite the current advances in clinical oncology, the prognosis of patients with resistant
diffuse large B cell lymphoma or relapse after high dose chemotherapy is dismal. Therefore
there is a need for the introduction of novel treatment regimens. This phase I/II trial
evaluates the safety and efficacy of combination bendamustine, gemcitabine, nivolumab and
rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. The safety
of combination treatment will be evaluated with the determination of recommended dose
schedule prior to expansion of enrollment to evaluate the antitumor activity of bendamustine,
gemcitabine, rituximab, and nivolumab.